Sandoz H108 Results Highlight Successful Growth In CEE

July 2008 | Company News Alert

Strong growth in Central and Eastern Europe (CEE) for Sandoz, Novartis' generics division, has made a significant contribution to the generics company's H108 results. In US dollar terms, sales grew by 13% year-on-year (y-o-y), to US$3.9. Growth in local currency sales, however, was only 2%, highlighting the impact of the weakened US dollar in Sandoz' first-half results. Operating income for the period grew by 1% to

If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.

If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.